Once the decision was bad, such as Merck solutions for launching and supporting painkiller Vioxx, it is easy to criticize. However, the result of poor performance is a good solution, which turned out to be lucky, or they are decisions that a bad result could have been foreseen? This case of pharmaceutical company Merck Vioxx product from initial design to launch and subsequent withdrawal, and believes that the decisions taken at each stage of Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal of the company and the value of shares of Merck. "Hide
by Mitchell A. Petersen, Rashmi Singhal Source: Kellogg School Management 23 pages. Publication Date: January 1, 2007. Prod. #: KEL289-PDF-ENG
Related Case Solutions & Analyses:
John Whitehead: Life in Leadership
Unlocking Sustained Business Value from IT Investments
First Commonwealth Financial Corp.
Challenges of Innovating for Sustainable Development
Performance Variability Dilemma
3M Optical Systems: Management Interviews Video
Alpha-Beta Technology Inc. (B): Trials with Betafectin
Au Bon Pain: The French Bakery Cafe the PartnerManager Program
Civil War Shoulder Arms (A)
MIS America Grupo Santander, Spanish Version
